Could a cholesterol shot boost stroke recovery?

NCT ID NCT07540741

Recruiting now Disease control Sponsor: First Affiliated Hospital of Harbin Medical University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether adding evolocumab (a powerful cholesterol-lowering drug) to standard statin therapy helps people recover better after a stroke caused by hardening of the large arteries. Researchers will follow 1000 adults aged 18-80 for 90 days, comparing those who get the combination to those who get statin alone. The goal is to see if the combination leads to better daily function and fewer repeat strokes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: evolocumab (a PCSK9 inhibitor) plus statin
What this could lead to: If successful, this could show that adding evolocumab to standard statin therapy helps more people recover better after a stroke caused by large-artery atherosclerosis.
What could go wrong: This is an observational study, not a randomized trial, so results may be less definitive. The benefit may be small, and there is a risk of side effects like injection-site reactions or muscle pain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ischemic stroke large artery stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE ISCHEMIC STROKE

Contacts and locations

Locations

Harbin, Heilongjiang, China, 150001
RECRUITING

Heilongjiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.